Table 3 Univariate Analysis of Risk Factors for Mortality

Male

8 (33%)

5 (50%)

0.4 (-0.17; -0.52 to 0.19)

Mean age, years (range)

47.7(3–68)

52 (35–68)

0.6 (-4.30; -14.9 to 6.32)^a

Acute leukemia

19 (79%)

9 (90%)

0.41 (-0.11; -0.35 to 6.32)

 - Myeloid

14 (58%)

8 (80%)

0.21 (-0.22; -0.53 to 0.10)

Other hematological disease

5 (21%)

1 (10%)

0.41 (-0.21; -0.53 to 0.10)

Intensive chemotherapy

20 (83%)

8 (80%)

0.58 (0.03; -0.25 to 0.32)

Other chemotherapy

1 (4%)

–

0.70 (0.04;-0.03 to 0.12)

Allogeneic stem cell transplant

3 (12%)

2 (20%)

0.46 (-0.08; -0.35 to 0.20)

Length of neutropenia episode (mean days, range)

 - With < 1000 neutrophils/mmc

19.4 (5–40)

18.9 (8–35)

0.70 (0.50; -5.90 to 6.90)^a

 - With < 100 neutrophils/mmc

11.2 (5–25)

8.3 (0–17)

0.29 (2.90; -3.29 to 9.09)^a

Onset of KPC-K.pneumoniae BSI

 - Shock

10 (42%)

7 (70%)

0.12 (-0.28;-0.62 to 0.06)

 -< 100 neutrophils/mmc

21 (87%)

8 (80%)

0.61 (0.07; -0.20 to 0.35)

 - KPC-K.pneumoniae BSI developing during inactive antibiotic treatment^b

3 (12.5%)

8 (80%)

 < 0.01 (-0.67;-0.95 to -0.39)

Active initial treatment

23 (96%)

3 (30%)

< 0.01 (-0.76; -1.02 to -0.50)

 - Combination

20 (83%)

2 (20%)

 < 0.01 (0.63; 0.34 to 0.92)

      With colistin

10

1

0.07 (0.32; 0.04 to 0.58)

      With ceftazidime/avibactam

10

1

0.07 (0.32; 0.04 to 0.58)

 -  Monotherapy

3 (12.5%)

1 (10%)

0.66 (0.02; -0.20 to 0.25)

      Tigecycline^c

2 (8.5%)

1 (10%)

0.66 (-0.16;-0.23 to 0.20)

      Ceftazidime/avibactam

1 (4.5%)

–

0.70 (0.4; -0.03 to 0.12)

Study period

 - Period 1 (March 2012–Dec 2013)

9 (37.5%)

9 (90%)

 < 0.01 (− 0.52; − 0.79 to − 0.25)

 - Period 2 (Jan 2017–Oct 2018)

15 (62.5%)

1 (10%)

 < 0.01 (0.52; 0.25 to 0.79)